RecruitingEarly Phase 1NCT03708627
Bimatoprost as a Treatment for Graves' Orbitopathy
The Role of Bimatoprost in Graves' Periorbitopathy
Sponsor
Johns Hopkins University
Enrollment
3 participants
Start Date
Nov 1, 2017
Study Type
INTERVENTIONAL
Conditions
Summary
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
Eligibility
Min Age: 18 Years
Exclusion Criteria1
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBimatoprost Ophthalmic
Bimatoprost, aka Lumigan, one drop in one eye nightly
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03708627
Related Trials
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
NCT074807201 location
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
NCT056783741 location
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
NCT061123402 locations
Hydroxychloroquine in Mild Graves' Orbitopathy
NCT051261472 locations
Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)
NCT031317261 location